Pfizer Inc. still believes in the potential for its Clostridioides difficile vaccine candidate PF-06425090 to have a meaningful impact on the lives of older people at high risk of potentially deadly c. difficile infections despite the fact that the vaccine failed to achieve the primary endpoint in the Phase III CLOVER clinical trial. The company said on 1 March that the candidate did not prevent primary c. diff infections but it reduced infections compared with placebo and eliminated hospitalizations for c. diff.
Pfizer Holds Out Hope For C. Diff Vaccine Despite Clinical, Commercial Failures
Sanofi’s Candidate Failed, Merck’s Zinplava Never Gained Traction
Pfizer’s Clostridioides difficile vaccine candidate missed a Phase III primary endpoint but the company may seek a path forward based on secondary endpoints even after past failures in the field.
More from Clinical Trials
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
More from R&D
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.